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Purpose: Severe asthma and asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) are difficult to control and are often 
associated with poor clinical outcomes. However, much is not understood regarding the diagnosis and treatment of severe asthma and ACOS. To 
evaluate the current perceptions of severe asthma and COPD among asthma and COPD specialists, we designed an e-mail and internet-based ques-
tionnaire survey. Methods: Subjects were selected based on clinical specialty from among the members of the Korean Academy of Asthma, Aller-
gy and Clinical Immunology and the Korean Academy of Tuberculosis and Respiratory Diseases. Of 432 subjects who received an e-mail invitation to 
the survey, 95 subjects, including 58 allergists and 37 pulmonologists, responded and submitted their answers online. Results: The specialists esti-
mated that the percentage of severe cases among total asthma patients in their practice was 13.9%±11.0%. Asthma aggravation by stepping 
down treatment was the most common subtype, followed by frequent exacerbation, uncontrolled asthma despite higher treatment steps, and seri-
ous exacerbation. ACOS was estimated to account for 20.7% of asthma, 38.0% of severe asthma, and 30.1% of COPD cases. A history of smoking, 
persistently low forced expiratory volume in 1 second (FEV1), and low FEV1 variation were most frequently classified as the major criteria for the di-
agnosis of ACOS among asthma patients. Among COPD patients, the highly selected major criteria for ACOS were high FEV1 variation, positive 
bronchodilator response, a personal history of allergies and positive airway hyperresponsiveness. Allergists and pulmonologists showed different 
assessments and opinions on asthma phenotyping, percentage, and diagnostic criteria for ACOS. Conclusions: Specialists had diverse perceptions 
and clinical practices regarding severe asthma and ACOS patients. This heterogeneity must be considered in future studies and strategy develop-
ment for severe asthma and ACOS.
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INTRODUCTION
Some patients with asthma fail to achieve acceptable control 
of their symptoms despite active treatment and modification of 
comorbidities. Severe asthma is often defined as asthma requir-
ing a high level of treatment to prevent it from becoming or re-
maining uncontrolled.1,2 Poor control of severe asthma is asso-
ciated with frequent exacerbation, high medical costs, and mor-
tality.3,4 Even with vigorous research to understand severe asth-
ma, neither an effective nor a comprehensive strategy has been 
determined to diagnose and treat severe asthma in clinical prac-
tice.
Some patients with asthma or chronic obstructive pulmonary 
disease (COPD) show features of both diseases, which are often 
determined to be asthma-COPD overlap syndrome (ACOS).5 
Many patients with previously diagnosed asthma or COPD alone 
are now recognized to have ACOS, particularly elderly patients.6 
Furthermore, ACOS has been found to have worse health out-
comes than asthma or COPD alone in terms of comorbidities, 
exacerbation frequencies, lung function decline, medication 
costs, and mortality.7-10 Like severe asthma, ACOS is hard to man-
age due to the lack of sound evidence for proper management. 
To date, prospective randomized controlled trials have not de-
termined uniform diagnostic criteria11 or an effective therapeu-
tic strategy for ACOS.12
Despite increased interest and research, there is a grey zone in 
clinical practices concerning severe asthma and ACOS that has 
not been well addressed in the guidelines of the Global Initia-
tive for Asthma (GINA)13 or the Global Initiative for Chronic Ob-
structive Lung Disease (GOLD).14 While a majority of the patients 
with severe asthma or ACOS are frequently referred to special-
ists, even the specialists’ practices for those patients have not 
been standardized. The purpose of this study was to investigate 
the current perceptions and practices of severe asthma and 
ACOS among asthma and COPD specialists. Using a question-
naire, we asked specialists how they diagnose and treat patients 
with severe asthma or ACOS.
MATERIALS AND METHODS
Subjects
We conducted a questionnaire survey of specialists in asthma 
and airway diseases from among the members of the Korean 
Academy of Asthma, Allergy and Clinical Immunology (KAAA-
CI) of the Korean Board of Internal Medicine, and members of 
the Study Group for Asthma, the Study Group for COPD, and 
the Study Group for Smoking Cessation of the Korean Academy 
of Tuberculosis and Respiratory Diseases (KATRD) using e-mail 
and a web-based questionnaire. The e-mail for the questionnaire 
survey was sent to 432 study subjects whose e-mail addresses 
were confirmed to be valid.
Questionnaire
The questionnaire on severe asthma and ACOS was developed 
by the Severe Asthma Work Group (SAWG) of the KAACI. The 
draft questionnaire for the survey was written and reviewed by 
all members of the SAWG. A pilot study was performed to test 
the questionnaire and included 15 members of the SAWG. Based 
on the feedback, the questionnaire was modified to provide 
more objective results. In the final questionnaire, written in the 
Korean language, the subjects were asked to include their age, 
gender, specialty, and primary field of clinical practice. The sur-
vey was comprised of three domains: 1) the diagnosis of severe 
asthma, 2) the treatment of severe asthma, and 3) the percep-
tion and diagnostic criteria for ACOS. To summarize the under-
standing and perceptions of the respondents, the subjects were 
instructed to answer the questions based on personal experi-
ences with severe asthma and ACOS in clinical practice, not on 
the published literature or general consensus. Various types of 
questions were used, including dichotomous, rating scale, mul-
tiple choice, and open-ended questions. Questions were devel-
oped to assess the clinical characteristics or subtypes of patients 
with severe asthma in each subject’s practice. In addition, the 
subjects were requested to provide the percentages (%) of pa-
tients with severe asthma among patients with asthma in their 
practices. We also assessed the diagnostic tests usually performed 
to phenotype severe asthma in clinical practice. Next, in the 
treatment of severe asthma, we asked the subjects to provide 
the percentage of patients who used each controller for asthma, 
as an open-ended question. For the questions on ACOS, we 
asked the subjects what percentage of all patients with asthma 
had ACOS. The same questions were also asked to assess the 
percentage of ACOS patients among all patients with severe 
asthma and COPD, respectively. We also asked the subjects to 
classify each clinical feature as major, minor, or no criteria for 
ACOS. We assessed the diagnostic criteria of ACOS among pa-
tients with COPD using similar questions. The complete survey 
is provided in Supplementary date 1.
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E-mail and online survey
We sent e-mails to 432 subjects containing an invitation to the 
online questionnaire. The subjects who agreed to participate 
accessed the questionnaire via the website link provided in the 
e-mail. The subjects were informed that their answers would 
be gathered anonymously. Usually, it took approximately 10 to 
15 minutes to answer all of the questions. Invitation e-mails 
were sent up to three times. Of the 432 subjects who received 
the invitation e-mail, 95 (22.0%) submitted answers to the ques-
tionnaire.
Statistical analysis
We used SPSS Statistics for Windows (Version 21.0, IBM Corp., 
Armonk, NY, USA) for statistical analysis. For each multiple-choice 
question, the number and percentage of the respondents are 
shown as number (%). May of the questions with numerical an-
swers asked for percentages of patients; those data are present-
ed as the mean±standard deviation. Comparisons between al-
lergists and pulmonologists were performed using a χ2 test (for 
nominal variables) or a Student’s t-test (for continuous variables). 
P values <0.05 were considered significant.
RESULTS
Characteristics of the respondents
The demographics and patterns of the clinical practices of the 
subjects (n=95) are presented in Table 1. All specialists were 
Korean and were certified internists. By subspecialty, there were 
58 allergists (61.1%) and 37 pulmonologists (38.9%). Most re-
spondents worked in university hospitals (n=77, 81.1%); others 
were in clinical practice in general hospitals (n=9, 9.5%) or pri-
vate clinics (n=9, 9.5%). Most specialists (n=85, 89.5%) accept-
ed adult patients only; others (n=10, 10.5%) accepted both adults 
and children. There were significant differences in age, gender, 
and institution of employment between the allergists and pul-
monologists.
Diagnosis of severe asthma
First, we attempted to assess the percentage of patients with 
severe asthma among all patients with asthma. To this purpose, 
we asked the specialists to provide the approximate percentage 
of severe asthma patients among total asthma patients in their 
clinical practice using an open-ended question. The mean per-
centage of severe asthma was 13.9%±11.0%, with a wide vari-
ance of estimation (range, 1%–70%; interquartile range [IQR], 
5–20). There was no difference between allergist and pulmon-
ologist responses (Fig. 1). As severe asthma is highly heteroge-
neous and includes different subtypes, we attempted to assess 
the variety of clinical features of severe asthma. We asked the 
subjects to estimate the percentage of patients with each sub-
type listed in the American Thoracic Society (ATS) guidelines15 
among their patients with severe asthma. The most commonly 
reported subtype was aggravation of symptoms due to stepping 
down to GINA asthma management step 3 or lower (22.4%±
20.9%), followed by frequent exacerbation (2 or more occasions 
of oral corticosteroid bursts per year; 20.9%±17.8%), uncon-
trolled asthma even at GINA step 4 or 5 (13.5%±12.6%), and 
serious exacerbation (one or more hospitalizations per year; 






















Table 1. Characteristics of the respondents







Age (year) 44.3±7.7 42.8±7.5 46.5±7.6 0.020
Male 59 (62.1) 31 (53.4) 28 (75.7) 0.033
Institution 0.035
   University hospital 77 (81.1) 51 (87.9) 26 (70.3)
   General hospital 9 (9.5) 5 (8.6) 4 (10.8)
   Clinic 9 (9.5) 2 (3.4) 7 (18.9)
Patient population 0.418
   Adults 85 (89.5) 53 (91.4) 32 (86.5)
   Adults and children 10 (10.5) 5 (8.6) 5 (13.5)
Values are presented as mean±standard deviation or number of patients (%). 
Bolded values denote statistical significance.
*Comparison between allergists and pulmonologists.
Fig. 2. Estimated percentage of asthma patients who had specific features of 
the disease.
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12.8%±10.8%) (Fig. 2). There were no significant differences in 
the estimated percentages of each subtype of severe asthma be-
tween the allergists and pulmonologists.
Next, we attempted to assess how frequently different diag-
nostic tests were used to determine asthma phenotypes in clin-
ical practice. The subjects were requested to select the tests that 
were usually performed at their practice to determine the phe-
notype of severe asthma. The most frequently used tests for asth-
ma phenotyping were peripheral blood counts (93.7%), skin prick 
tests (SPTs), serum specific immunoglobulin E (IgE) (93.7%), 
and the measurement of serum total IgE (93.7%) (Table 2). Oth-
er tests included chest computed tomography (CT) (65.3%), in-
duced sputum analysis (45.3%), measurement of exhaled nitric 
oxide (26.3%), and the aspirin provocation test (16.8%). Aller-
gists used induced sputum analysis, exhaled nitric oxide, and 
the aspirin provocation test more frequently than pulmonolo-
gists, while pulmonologists tended to use peripheral blood cell 
counts more frequently than allergists.
Treatment of severe asthma
In the management of patients with severe asthma, poor re-
sponse to medication is challenging. These patients fail to achieve 
or maintain asthma control even at a higher level of asthma man-
agement, including high dose inhaled corticosteroids (ICS) and 
long-acting beta-2 agonists (LABA). Thus, we attempted to as-
sess what medications are used for pharmacologic treatment of 
severe asthma. The subjects were asked to estimate the percent-
age of patients using each medication added to high-dose ICS/
LABA and leukotriene receptor antagonists. The most frequent-
ly used add-on medications were theophylline (46.0%±32.7%) 
Table 3. Difficulties in the management of severe asthma 
Factor Total (n=95) Allergists (n=58) Pulmonologists (n=37) P value*
Lack of effective medication 83 (87.4) 53 (91.4) 30 (81.1) 0.141
Concern over adverse reactions to medication 45 (47.4) 24 (41.4) 21 (56.8) 0.143
Concern over insurance cuts 24 (25.3) 16 (27.6) 8 (21.6) 0.514
Fear of misdiagnosis 23 (24.2) 17 (29.3) 6 (16.2) 0.146
Poor patient compliance 23 (24.2) 16 (27.6) 7 (18.9) 0.336
Lack of severe asthma guideline 18 (18.9) 12 (20.7) 6 (16.2) 0.587
Difficulty with the patient relationship 13 (13.7) 6 (10.3) 7 (18.9) 0.236
High medical costs 12 (12.6) 8 (13.8) 4 (10.8) 0.670
Values are presented as number of patients (%). Lack of effective drugs (87.4%), concern over adverse reactions to medications (47.4%), concern over insurance cuts 
(25.3%), fear of misdiagnosis (24.2%), poor patient compliance (24.2%), lack of severe asthma guidelines (18.9%), difficulty with the patient relationship (13.7%), 
and high medical costs (12.6%).
*Comparison between allergists and pulmonologists.
Table 2. Diagnostic tests used to determine the phenotypes of severe asthma
Test Total (n=95) Allergists (n=58) Pulmonologists (n=37) P value*
Peripheral blood cell counts 89 (93.7) 52 (89.7) 37 (100.0) 0.043
SPT or serum specific IgE 89 (93.7) 55 (94.8) 34 (91.9) 0.566
Serum total IgE 89 (93.7) 54 (93.1) 35 (94.6) 0.771
Chest CT 62 (65.3) 42 (72.4) 20 (54.1) 0.067
Induced sputum eosinophil count 43 (45.3) 32 (55.2) 11 (29.7) 0.015
Exhaled nitric oxide 25 (26.3) 21 (36.2) 4 (10.8) 0.006
Aspirin provocation test 16 (16.8) 15 (25.9) 1 (2.7) 0.003
Values are presented as number of patients (%). Bolded values denote statistical significance.
SPT, skin prick test; IgE, immunoglobulin E; CT, computed tomography.
*Comparison between allergists and pulmonologists.
Fig. 3. Estimated percentage of patients with severe asthma who were pre-
scribed add-on asthma controllers.
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and tiotropium (45.5%±29.4%) (Fig. 3). The specialists respond-
ed that patients with severe asthma were prescribed very high 
dose ICS (more than the approved dose) (16.6%±24.1%), regu-
lar use of oral corticosteroids (less than 20 mg/day of predniso-
lone) (14.7%±13.3%), roflumilast (9.3%±15.7%), two or more 
different types of ICS (7.5%±18.4%), regular use of oral cortico-
steroids (20 mg/day or more of prednisolone) (5.2%±11.6%), 
omalizumab (3.3%±12.2%), methotrexate (0.3%±1.4%), and 
cyclosporine (0.1%±0.6%) for treatment of severe asthma. There 
was no difference in the prescription of add-on medications 
between allergists and pulmonologists.
Next, we assessed the difficulties specialists encountered when 
treating severe asthma. The subjects reported the following fac-
tors as major difficulties of severe asthma management: lack of 
effective drugs (87.4%), concern over adverse reactions to med-
ications (47.4%), concern over insurance cuts (25.3%), fear of 
misdiagnosis (24.2%), poor patient compliance (24.2%), lack of 
severe asthma guidelines (18.9%), difficulty with the patient re-
lationship (13.7%), and high medical costs (12.6%). No differ-
ence was found between allergists and pulmonologists in their 
experience of difficulties in the management of severe asthma 
(Table 3).
Perception and diagnostic criteria of ACOS
The second topic of this survey was the perception of ACOS 
among specialists. First, we asked the subjects to provide the 
estimated percentage of ACOS patients among patients with 
asthma in their clinical practice. Similar questions requested 
the percentage of ACOS patients among severe asthma cases 
and among COPD cases. The results of these three questions 
are illustrated in Fig. 4. The specialists estimated that the per-
centage of ACOS of asthma was 20.7%±10.7%. The estimated 
percentage of ACOS among patients with severe asthma was 
38.0%±20.9%, and that of ACOS among patients with COPD 
was 30.1%±21.3%. The mean values of the percentages of ACOS 
in overall asthma and severe asthma patients from the allergists’ 
perspective were not different from those of pulmonologists. 
However, the estimated percentage of ACOS in patients with 
COPD was higher according to allergists than pulmonologists 
(35.5%±23.6% vs. 22.6%±14.8%; P=0.002).
Next, we attempted to identify the most important features in 
ACOS diagnosis. As ACOS is accepted as a subgroup of both asth-
ma and COPD, we assumed that diagnosis of ACOS in patients 
with asthma would be different than diagnosis in patients with 
COPD. Thus, we asked the subjects two questions regarding the 
diagnosis of ACOS. First, we asked the specialists to classify each 
feature as a major or a minor criterion for the diagnosis of ACOS. 
The features most often classified as major criteria (>70% of the 
subjects) included a history of smoking (83.2%), persistently 
low forced expiratory volume in 1 second (FEV1 <80% of the 
predicted value, 81.1%), and low variation of FEV1 over time 
(71.6%). The features not consistently classified as major crite-
ria (<70%) included emphysema on chest images (67.4%), neg-
ative bronchodilator response (BDR) (54.7%), older age at on-
set of symptoms (≥40 years) (52.6%), no personal history of al-
lergic diseases (27.4%), negative SPTs (14.7%), no family history 
of allergic diseases (11.6%), no sputum eosinophilia (9.5%), low 
serum total IgE (7.4%), and low exhaled nitric oxide concentra-
tion (3.2%) (Table 4). Allergists selected emphysema on chest 
images as a major criterion more frequently than pulmonolo-
gists (75.9% vs. 54.1%; P=0.039), while pulmonologists more 
commonly selected older age at onset of symptoms (70.3% vs. 
41.4%; P=0.010) and low serum total IgE (13.5% vs. 3.4%; P=  
0.010).
The second question asked about the diagnosis of ACOS in 
patients with COPD. Most specialists responded that high FEV1 
variation over time (86.3%), positive BDR (79.0%), a personal 
history of allergic disease (73.7%) and positive airway hyper-re-
sponsiveness (AHR) (71.6%) were major criteria for the diagno-
sis of ACOS in patients with COPD. The features less often clas-
sified as major criteria were no history of smoking (57.3%), young 
age of onset (<40 years) (63.2%), no history of smoking (56.8%), 
positive SPT (54.7%), high serum total IgE (50.5%), sputum eo-
sinophilia (45.3%), family history of allergic diseases (40.0%), 
wheeze (35.8%), high exhaled nitric oxide concentration (31.6%), 
and lack of emphysema on chest images (23.2%) (Table 5). Of 
these features, the allergists tended to favour exhaled nitric ox-
ide concentration in the determination of ACOS among COPD 
patients compared to pulmonologists (41.4% vs. 16.2%; P=0.008). 
However, the pulmonologists selected high serum total IgE as 
the diagnostic criterion for ACOS more frequently than allergists 
(54.1% vs. 48.3%; P=0.040).
Finally, we asked if ACOS in asthma and ACOS in COPD were 
the same disease. Overall, 37.9% of the specialists agreed that 
the two diseases are the same. More allergists tended to agree 
with this suggestion than pulmonologists (44.8% vs. 27.0%; P=  
Fig. 4. Estimated proportion of patients with asthma, severe asthma, and COPD 
who had ACOS. COPD, chronic obstructive pulmonary disease; ACOS, asthma-
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0.062). These findings suggest that the specialists consider dif-
ferent criteria for the diagnosis of ACOS in patients with asthma 
compared to patients with COPD. Moreover, the diagnostic cri-
teria for ACOS perceived by the allergists were somewhat dis-
similar to those perceived by the pulmonologists.
 
DISCUSSION
Severe asthma and ACOS are receiving more attention due to 
serious morbidity and poor clinical outcomes. However, ambi-
guity and uncertainty still exist in the understanding of severe 
asthma and ACOS, even among specialists. In this study, we es-









History of smoking Major 79 (83.2) 46 (79.3) 33 (89.2) 0.210
Minor 16 (16.8) 12 (20.7) 4 (10.8)
No 0 (0.0) 0 (0.0) 0 (0.0)
Persistently low FEV1 (<80% predicted) Major 77 (81.1) 45 (77.6) 32 (86.5) 0.527
Minor 12 (12.6) 9 (15.5) 3 (8.1)
No 6 (6.3) 4 (6.9) 2 (5.4)
Low FEV1 variation over time Major 68 (71.6) 41 (70.7) 27 (73.0) 0.251
Minor 23 (24.2) 13 (22.4) 10 (27.0)
No 4 (4.2) 4 (6.9) 0 (0.0)
Emphysema on chest images Major 64 (67.4) 44 (75.9) 20 (54.1) 0.039
Minor 26 (27.4) 13 (22.4) 13 (35.1)
No 5 (5.3) 1 (1.7) 4 (10.8)
Negative BDR Major 52 (54.7) 30 (51.7) 22 (59.5) 0.710
Minor 36 (37.9) 23 (39.7) 13 (35.1)
No 7 (7.4) 5 (8.6) 2 (5.4)
Age of onset ≥40 years Major 50 (52.6) 24 (41.4) 26 (70.3) 0.010
Minor 39 (41.1) 28 (48.3) 11 (29.7)
No 6 (6.3) 6 (10.3) 0 (0.0)
No personal history of allergic disease Major 26 (27.4) 14 (24.1) 12 (32.4) 0.117
Minor 53 (55.8) 31 (53.4) 22 (59.5)
No 16 (16.8) 13 (22.4) 3 (8.1)
Negative SPT Major 14 (14.7) 10 (17.2) 4 (10.8) 0.095
Minor 51 (53.7) 26 (44.8) 25 (67.6)
No 30 (31.6) 22 (37.9) 8 (21.6)
No family history of allergic disease Major 11 (11.6) 6 (10.3) 5 (13.5) 0.267
Minor 60 (63.2) 34 (58.6) 26 (70.3)
No 24 (25.3) 18 (31.0) 6 (16.2)
No sputum eosinophilia (<3%) Major 9 (9.5) 4 (6.9) 5 (13.5) 0.396
Minor 57 (60.0) 34 (58.6) 23 (62.2)
No 29 (30.5) 20 (34.5) 9 (24.3)
Low serum total IgE Major 7 (7.4) 2 (3.4) 5 (13.5) 0.010
Minor 51 (53.7) 27 (46.6) 24 (64.9)
No 37 (39.0) 29 (50.0) 8 (21.6)
Low exhaled nitric oxide (<25 ppb) Major 3 (3.2) 2 (3.4) 1 (2.7) 0.732
Minor 44 (46.3) 25 (43.1) 19 (51.4)
No 48 (50.5) 31 (53.4) 17 (45.9)
Values are presented as number of patients (%). Bolded values denote statistical significance.
ACOS, asthma-chronic obstructive pulmonary disease overlap syndrome; FEV1, forced expiratory volume in 1 second; BDR, bronchodilator response; SPT, skin prick 
test; IgE, immunoglobulin E.
*Characteristics are listed in descending order in terms of % response of major criteria; †comparison between allergists and pulmonologists.
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timated the percentages and phenotypes of severe asthma and 
ACOS in the clinical practices of specialists. We also evaluated 
the patterns of diagnosis and treatment of severe asthma in clin-
ical practice. Thus, we assessed the current perceptions of se-
vere asthma and ACOS among specialists in airway diseases 
using a questionnaire-based survey.









High FEV1 variation over time Major 82 (86.3) 50 (86.2) 32 (86.5) 0.479
Minor 11 (11.6) 6 (10.3) 5 (13.5)
No 2 (2.1) 2 (3.4) 0 (0.0)
Positive BDR Major 75 (79.0) 50 (86.2) 25 (67.6) 0.094
Minor 15 (15.8) 6 (10.3) 9 (24.3)
No 5 (5.3) 2 (3.4) 3 (8.1)
Personal history of allergic diseases Major 70 (73.7) 41 (70.7) 29 (78.4) 0.708
Minor 22 (23.2) 15 (25.9) 7 (18.9)
No 3 (3.2) 2 (3.4) 1 (2.7)
Positive AHR test Major 68 (71.6) 40 (69.0) 28 (75.7) 0.496
Minor 21 (22.1) 13 (22.4) 8 (21.6)
No 6 (6.3) 5 (8.6) 1 (2.7)
Age of onset <40 years Major 60 (63.2) 28 (48.3) 32 (64.9) 0.256
Minor 30 (31.6) 25 (43.1) 5 (27.0)
No 5 (5.3) 5 (8.6) 0 (8.1)
No history of smoking Major 54 (56.8) 31 (53.4) 23 (62.2) 0.555
Minor 36 (37.9) 23 (39.7) 13 (35.1)
No 5 (5.3) 4 (6.9) 1 (2.7)
Positive SPT Major 52 (54.7) 32 (55.2) 20 (54.1) 0.091
Minor 33 (34.7) 17 (29.3) 16 (43.2)
No 10 (10.5) 9 (15.5) 1 (2.7)
High serum total IgE Major 48 (50.5) 28 (48.3) 20 (54.1) 0.040
Minor 34 (35.8) 18 (31.0) 16 (43.2)
No 13 (13.7) 12 (20.7) 1 (2.7)
Sputum eosinophilia (>3%) Major 43 (45.3) 31 (53.4) 12 (32.4) 0.118
Minor 41 (43.2) 22 (37.9) 19 (51.4)
No 11 (11.6) 5 (8.6) 6 (16.2)
Family history of allergic diseases Major 38 (40.0) 20 (34.5) 18 (48.6) 0.072
Minor 46 (48.4) 28 (48.3) 18 (48.6)
No 11 (11.6) 10 (17.2) 1 (2.7)
Wheeze Major 34 (35.8) 19 (32.8) 15 (40.5) 0.742
Minor 50 (52.6) 32 (55.2) 18 (48.6)
No 11 (11.6) 7 (12.1) 4 (10.8)
High exhaled nitric oxide (>50 ppb) Major 30 (31.6) 24 (41.4) 6 (16.2) 0.008
Minor 39 (41.1) 17 (29.3) 22 (59.5)
No 26 (27.4) 17 (29.3) 9 (24.3)
Lack of emphysema on chest images Major 22 (23.2) 15 (25.9) 7 (18.9) 0.720
Minor 60 (63.2) 35 (60.3) 25 (67.6)
No 13 (13.7) 8 (13.8) 5 (13.5)
Values are presented as number of patients (%). Bolded values denote statistical significance.
ACOS, asthma-chronic obstructive pulmonary disease overlap syndrome; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; 
BDR, bronchodilator response; AHR, airway hyper-responsiveness; SPT, skin prick test; IgE, immunoglobulin E.
*Characteristics are listed in descending order in terms of % response of major criteria; †comparison between allergists and pulmonologists.
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It is frequently said that 5%-10% of patients with asthma have 
severe asthma. However, this estimation varies depending on 
the diagnostic criteria and population. Studies so far have shown 
that approximately 3%-10% of patients with asthma in the gen-
eral population suffer from severe asthma.16-18 However, the pro-
portion of patients with severe asthma was determined to be 
10%-25% of asthma patients in a specialty clinic.19 In our sur-
vey, the specialists’ estimation of severe asthma prevalence was 
high, although estimates varied widely. As most respondents of 
this survey worked in university hospitals or general hospitals, 
these percentages reflect the population of severe asthma in 
specialist clinics, not in the general population. The reasons for 
the diversity of estimated prevalence could be due to the lack of 
a given definition of severe asthma, heterogeneity of the institu-
tions, and patient populations.
Definitions of severe or refractory asthma have changed over 
time,1,2,15,20 and there is currently no universally accepted defini-
tion. However, it is acknowledged that severe asthma is hetero-
geneous and has many phenotypes and endotypes.21 There-
fore, we asked specialists how frequently they observed each 
clinical subtype or characteristic of severe asthma, based on the 
diagnostic criteria of refractory asthma used by the ATS.15 Inter-
estingly, the most common clinical features of severe asthma 
were aggravation of symptoms by stepping down treatment and 
frequent exacerbations, while the proportion of uncontrolled 
symptoms at GINA treatment steps 4-5 was not so high. These 
findings suggest that many patients with severe asthma require 
prolonged and higher medications to maintain control even 
though their symptoms are controlled.
Phenotypes are defined as composite and observable charac-
teristics resulting from the interaction of genetic and environ-
mental effects.1 Phenotype-based asthma management has not 
been well emphasized to date, with the exception of the identi-
fication of allergic asthma for the use of anti-IgE. More than 90% 
of the specialists in this study measured peripheral blood cell 
eosinophil count and allergic status using total and serum spe-
cific IgE and a SPT for aeroallergens. Approximately 65% used a 
chest CT, usually to manage severe asthma. The chest CT is use-
ful for the differential diagnosis of other respiratory diseases that 
mimic asthma, and for identification of emphysema, a feature 
of COPD. Measurement of sputum eosinophils, exhaled nitric 
oxide, and the aspirin provocation test were more frequently 
used by allergists than pulmonologists, suggesting that pheno-
typing of asthma has been more widely accepted by allergy spe-
cialists. In the near future, asthma phenotyping will be more 
important in cases of severe asthma, with introduction of new 
biological agents targeting type 2 inflammation, such as inter-
leukin (IL)-5, IL-4, and IL-13.22 Problems in the treatment of se-
vere asthma include the lack of guidance in the determination 
of asthma phenotypes and difficulty in the measurement and 
integration of various biomarkers.23 Accurate, informative, and 
easy-to-measure biomarkers are needed to phenotype asthma.
One of the primary difficulties in the management of severe 
asthma is that there is no effective add-on treatment when asth-
ma is uncontrolled, despite the use of high dose ICS and LABA. 
Lack of effective medication leads to the use of multiple medi-
cations to achieve and maintain asthma control. Moreover, poly-
pharmacy in severe asthma is associated with increased direct 
medical costs and risk of adverse reactions.24 Thus, we asked 
how many patients used add-on medications in addition to high-
dose ICS/LABA and leukotriene receptor antagonists. As shown 
in Figure 3, the most frequently prescribed medications were 
theophylline and tiotropium, as recommended in the GINA gui-
delines.13 Oral corticosteroids were more commonly prescribed 
at low doses (<20 mg/day) than at high doses (≥20 mg/day). 
Omalizumab, which was the only available biological agent ap-
proved for use in severe allergic asthma at the time of this sur-
vey, was used in a small number of patients with severe asth-
ma. Despite its proven efficacy in clinical trials and clinical prac-
tice,25 the low use of omalizumab might be associated with one 
or more disadvantages, including high cost, complexity of ad-
ministration, risk of serious adverse reactions, lack of efficacy, 
and relatively narrow indication in severe asthma.26 In the sur-
vey regarding the difficulties of management of severe asthma, 
the lack of effective medications and concern over adverse re-
actions were most commonly selected (Table 3). The results of 
this study showed that the off-label use of medications, such as 
very high dose ICS, multiple ICSs, roflumilast, methotrexate, 
and cyclosporin, was also being tried in some patients with se-
vere asthma. While these medications have failed to show sig-
nificant overall efficacy in patients with severe asthma, some 
patients with specific phenotypes or endotypes might benefit 
from specific treatment that is not currently approved. As a fu-
ture medication, personalized precision medicine targeting a 
treatable phenotype or pathophysiology is expected to be avail-
able soon for the management of severe asthma.27 In addition 
to the sophisticated use of available medications, we must de-
velop new effective therapeutic agents for severe asthma with 
fewer adverse effects.
ACOS is currently receiving a great deal of attention. Studies 
to date have shown that its clinical outcome is poorer than asth-
ma or COPD alone, with a higher rate of exacerbations and great-
er mortality.7,8 While the prevalence of ACOS among chronic 
airway diseases has been reported to be approximately 20%,28 it 
varies depending on the study design, population, and defini-
tion of ACOS. In our survey, the percentage of ACOS patients 
was estimated to be 20.7% in patients with asthma, 38.0% in pa-
tients with severe asthma, and 30.1% in patients with COPD. 
This estimate is based on patient populations of each subject, 
not the general population, reflecting actual experience in a spe-
cialty clinic. The problem is that there is no universally accept-
ed working definition of ACOS. Thus, it is likely that even a spe-
cialist might use their own definition of ACOS. The difference in 
the diagnostic criteria leads to a wide variance of the prevalence 
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of ACOS in various types of studies.29 Furthermore, the applica-
tion of different ACOS definitions or diagnostic criteria also leads 
to dissimilar clinical characteristics and outcomes.30 Interest-
ingly, most diagnostic criteria were developed to define ACOS 
among patients with COPD,31-34 not among patients with asth-
ma. As in the consensus criteria of ACOS in Spain,31 we asked 
the specialists to name the key features of COPD that are con-
sidered in the diagnosis of ACOS in patients with asthma. The 
characteristics of COPD were given in detail, and were classi-
fied as major or minor criteria by the respondents. Intriguingly, 
most respondents selected a history of smoking as a major cri-
terion for ACOS in asthma. It is obvious that smoking affects 
lung function decline and contributes to the development of 
COPD.35 However, considering that a high percentage of COPD 
patients have never smoked,36 it seems an oversimplification to 
consider only smoking in the determination of ACOS. In addi-
tion to smoking, a spirometric index such as persistently low 
FEV1 or low FEV1 variation over time were selected as major 
characteristics of ACOS. These findings suggest that specialist 
support in the diagnosis of ACOS in patients with asthma should 
be made in consideration of smoking and changes in lung func-
tion over time. Emphysema was also selected as a major criteri-
on by allergists more than pulmonologists. Although the pres-
ence of emphysema does not indicate COPD per se, COPD must 
be considered in asthma patients showing emphysema on chest 
images. Furthermore, emphysema by itself might be a link be-
tween asthma and COPD, both in smokers and in patients who 
have never smoked.37
There have been attempts by a Spanish group and a global ex-
pert panel, the ATS roundtable discussion, to define diagnostic 
criteria by consensus.31,34 Both consensus definitions included 
the previous diagnosis of asthma and positive BDRs as major 
criteria.38 While a positive BDR was selected as a major criteri-
on by many respondents, the highest scores were given to high 
FEV1 variation over time and AHR. In a recent study by Tkaco-
va et al.,39 AHR, not BDR, was found to be associated with ac-
celerated lung function decline and higher mortality in patients 
with COPD. These findings suggest that AHR should be consid-
ered as a key element in the determination of ACOS. The previ-
ous history of asthma diagnosis before 40 years of age was clas-
sified as a major criterion in previous consensus documents on 
ACOS. However, many adult patients with asthma in some coun-
tries, including Korea, experience symptoms onset at a very old 
age, and the duration of asthma is very short.19 Given this late 
diagnosis of asthma, the previous diagnosis before 40 years of 
age could not be practically and universally used. Thus, we did 
not include the previous diagnosis of asthma as a candidate char-
acteristic of ACOS in this study. Rather, we added a personal 
history of allergic diseases, which was selected as a major crite-
rion by many specialists. As rhinitis and atopy are considered 
significant risk factors for the future development of asthma,40 it 
seems reasonable to consider a past history of allergies when 
diagnosing ACOS in patients with COPD.
Two different pathways may exist for the development of ACOS; 
it may stem from asthma, or from COPD.41 Thus, some experts 
suggest that ACOS can be divided into asthma with features of 
COPD (COPD-like asthma) and COPD with features of asthma 
(asthma-like COPD).42 Our data support this idea, as more than 
half of the respondents (62.1%) did not agree that asthma pa-
tients diagnosed with ACOS are the same population as COPD 
patients diagnosed with ACOS. As the previously developed 
consensus definition of ACOS was developed in order to define 
ACOS as a subtype of COPD, there are limitations to applying 
that definition to the whole population of ACOS patients. ACOS 
cannot be a single disease entity or a subtype of COPD, as stat-
ed in the GINA update in 2017.13 It is acknowledged that asth-
ma is a heterogeneous disease, as is COPD.43 Therefore, it is ap-
parent that ACOS, which shares features of both asthma and 
COPD, is a heterogeneous disease and has various phenotypes.44,45 
Understanding of ACOS varies even among specialists. Univer-
sal application of the definition of ACOS looks tempting, but is 
impractical both in clinical practice and research.
A few studies regarding the perceptions and insights of ACOS 
have been published, primarily by pulmonologists.46,47 The ad-
vantages of our study are the inclusion of both pulmonologists 
and allergists, and the comparison of their insights and clinical 
practices concerning severe asthma and ACOS. Some differ-
ences according to subspecialty (allergy or pulmonology) were 
found in responses to some questions of severe asthma and 
ACOS. Differences included the use of diagnostic tests in asth-
ma phenotyping, assessment of the percentage of the ACOS 
population among COPD patients, and the definition of ACOS 
among patients with asthma or COPD. Previous studies also 
showed that the characteristics and management of asthma 
differed between allergists and pulmonologists.48,49 We specu-
late that this discord according to subspecialty resulted from 
the variance in patient populations and different perspectives 
on asthma and COPD.
However, the results of this study must be interpreted with cau-
tion. As this survey was based on the views of the participants 
and the response rate of the invited subjects was low, the find-
ings cannot be over-generalized. In this regard, the difference 
between allergists and pulmonologists cannot be over-empha-
sized, since the respondents do not represent for each subspe-
cialty group. Moreover, as this was a nationwide survey in Ko-
rea, it might reflect country- or ethnic-specific conditions of clin-
ical practices and insurance status. Lastly, because the respons-
es of the respondents were based on their own experience and 
perceptions, not on the objective assessment from the patient 
cohort or registry, the results of this study might be different from 
the real-world assessments.
In conclusion, the results showed that specialists’ estimation 
of the prevalence of severe asthma and ACOS varies widely. Their 
understandings and practices of severe asthma and ACOS di-
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verged on some points depending on their specialty. These di-
verse opinions should be considered in future studies and the 
development of strategies to manage severe asthma and ACOS.
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Supplement 1. Survey Questionnaire
Basic information 
1. What is your age? (________________)
2. What is your gender?
1) male
2) female
3. What is your specialty board?
1) allergy
2) pulmonology
3) other specialty board
4) not a specialist










I. Diagnosis of severe asthma
1.  What percentage of patients with severe asthma in your practice have the following clinical features? (The sum of the subtypes 
may be over 100%.)
Uncontrolled asthma symptoms despite gina step 4-5 treatment __________%
Controlled asthma symptoms at gina step 4-5, but symptoms are aggravated by stepping down __________%
Serious exacerbation (≥1 hospitalization per year) __________%
Frequent exacerbation (≥2 uses of oral corticosteroid rescue per year) __________%
2.  What is the approximate percentage of patients with severe asthma among the total number of asthma patients in your practice? 
(__________%)
3.  The phenotype of severe asthma is known to be diverse. Please indicate the usual tests for the classification of severe asthma 
phenotypes in your practice.
Test Yes No
Serum total ige ☐ ☐
Peripheral blood cell count ☐ ☐
Induced sputum eosinophil count ☐ ☐
Exhaled nitric oxide ☐ ☐
Allergen skin tests or serum specific ige measurement ☐ ☐
Chest computed tomography (ct) ☐ ☐
Aspirin provocation test ☐ ☐
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4. What percentage of patients with severe asthma in your practice have the following diseases? 
Allergic rhinitis __________%
Gastro-oesophageal reflux disease (GERD) __________%
Obesity __________%
Sleep apnoea __________%
Depression or anxiety disorder __________%
Aspirin intolerance __________%
II. Treatment of severe asthma
1.  Of the patients with severe asthma you are seeing, what percentages use the following drugs as controller medications in addi-
tion to high-dose inhaled corticosteroids (ICS) / long-acting beta-2 agonists (LABA) and leukotriene receptor antagonists?
Very high dose ics __________%
Two or more icss __________%
Oral corticosteroids (≥20 mg/day) __________%







2. What is most difficult when you see patients with severe asthma? (Multiple answers possible)
1) no effective add-on drugs
2) concern over misdiagnosis
3) difficulty with the patient relationship
4) insurance cuts
5) low patient compliance
6) high medical expenses
7) concern over adverse drug reactions
8) lack of severe asthma guidelines
III. Asthma-COPD overlap syndrome (ACOS)
1.  What is the approximate percentage of patients with ACOS among the total number of asthma patients in your practice? 
(__________%)
2.  What is the approximate percentage of patients with severe asthma among the total number of asthma patients in your practice? 
(__________%)
3.  What is the approximate percentage of the patients with ACOS among the total number of COPD patients in your practice? 
(__________%)
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4.  This question is about the ACOS criteria among patients initially diagnosed with and treated for asthma. The list includes pos-
sible items which can be considered in the diagnosis of ACOS among asthma patients. Please check if each item in the list could 
be a major or minor criterion or not. 
Diagnostic criterion Major Minor No
Older age of onset (≥40 years old) ☐ ☐ ☐
History of smoking ☐ ☐ ☐
No personal history of allergic diseases ☐ ☐ ☐
No family history of allergic diseases ☐ ☐ ☐
Negative skin prick test ☐ ☐ ☐
Low serum total IgE ☐ ☐ ☐
Persistently low FEV1 <80% predicted ☐ ☐ ☐
Low FEV1 variation over time ☐ ☐ ☐
Negative bronchodilator response ☐ ☐ ☐
No sputum eosinophilia (<3%) ☐ ☐ ☐
Low exhaled nitric oxide (<25 ppb) ☐ ☐ ☐
Emphysema on chest images ☐ ☐ ☐
5.  This question is about the ACOS criteria among patients initially diagnosed with and treated for COPD. The list includes possi-
ble items considered in the diagnosis of ACOS among asthma patients. Please check if each item in the list could be a major or 
minor criterion or not. 
Diagnostic criterion Major Minor No
Younger age of onset (<40 years old) ☐ ☐ ☐
Wheeze ☐ ☐ ☐
No history of smoking ☐ ☐ ☐
Personal history of allergic diseases ☐ ☐ ☐
Family history of allergic diseases ☐ ☐ ☐
Positive skin prick test ☐ ☐ ☐
High serum total IgE ☐ ☐ ☐
High FEV1 variation over time ☐ ☐ ☐
Positive bronchodilator response (12% and 200 mL) ☐ ☐ ☐
Positive airway hyper-responsiveness test ☐ ☐ ☐
Sputum eosinophilia (>3%) ☐ ☐ ☐
High exhaled nitric oxide (>50 ppb) ☐ ☐ ☐
Lack of emphysema on chest images ☐ ☐ ☐
6. Do you agree that asthma patients diagnosed with ACOS are the same population as COPD patients diagnosed with ACOS?
1) Yes
2) No
